Overview

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.
Phase:
Phase 2
Details
Lead Sponsor:
California Retina Consultants
Collaborator:
Novartis
Treatments:
Bevacizumab
Verteporfin